SAMPLE SIZE CALCULATIONS Sample Clauses

SAMPLE SIZE CALCULATIONS. Assuming a responder rate (microbiological cure) of 75% in the Solosec treatment group and a 40% placebo response rate and based on the use of a two-sided, two-sample comparison of proportions at the alpha=0.05 level of significance, a sample size of 100 patients (50 patients in each group) who meet the mITT criteria will provide approximately 95% power to demonstrate a statistically significant difference between Solosec and placebo. Assuming 70% of patients randomized in the study will meet the mITT criteria, approximately 144 patients will be enrolled into the study.
Sample 1
AutoNDA by SimpleDocs
SAMPLE SIZE CALCULATIONS. Estimated rates of subsequent MRSA infection were based on the available literature. For patients without nasal colonization it was estimated that 2.5% of the population would develop a MRSA infection during follow-up while 10% of those with low nasal colonization (Ct > 24) and 30% of those with high (Ct ≤ 24) nasal colonization would subsequently develop an infection. Using a power of 80% and an alpha of 0.05, approximately 28 patients would be needed to show an effect when comparing high colonization to no colonization, 62 patients needed to compare high colonization to low colonization, and 150 patients comparing low colonization to no colonization. Approximately 50 patients per month are admitted to the AVAMC with MRSA nasal colonization. Of these patients, 30% have high nasal MRSA burden (≈ 15/month) and 70% have low nasal MRSA burden (≈ 35/month). Based on the above estimates and admission patterns at the AVAMC, it was estimated that four months worth of admission data would be needed to provide an adequate sample size. Statistical Analysis Descriptive statistics were used to compare the study population stratified by colonization status (negative, low burden, high burden). The purpose of this comparison was to identify potential factors that are associated with the exposure variable (colonization status). Differences in proportions of categorical variables (including demographic and clinical characteristics and co-morbidities) were tested using χ2. If expected cell counts were less than 5, Xxxxxx’x exact test was utilized. Continuous variables were analyzed with a one-way analysis of variance to compare means or two- sample T test. A p-value of ≤ 0.05 was considered significant. Unadjusted risk ratios were obtained for all covariates and the outcome in univariate analysis. Due to the limited published clinical data on nasal colonization burden, an exploratory analysis for potential interaction terms was performed. In this analysis, the study population was stratified on individual covariate levels and risk ratios for each level of the exposure variable (colonization status) were compared with the Xxxxxxx-Day test. A p-value ≤ 0.10 was considered significant in addition to biologically plausible interaction terms. A multivariate logistic regression model was used to analyze the relationship between MRSA nasal colonization and subsequent infection. All covariates significant in univariate analysis (P < 0.10) and those considered clinically or epidemio...
Sample 1
SAMPLE SIZE CALCULATIONS. The American Psychological Association (APA; 1999) recommends a minimum sample size of 100 for a norm-referenced test. Further, for the development of regression-based norms for a psychological test which is short in length, with a small number of item scores, a minimum sample size of 100 is recommended (Oosterhuis, van der Ark, & Sijtsma, 2016). The previous unpublished norming study on the CVWMT-I (Xxxx, 2016) had a sample size of N = 37. Based on these recommendations, the previous study and time constraints on the current study, the statistical tool, Quantifying the Uncertainty Attached to Normative Data (QUAND; Xxxxxxxx & Garthwaite, 2008) was used to compare the 95% confidence intervals for a sample where N = 37 and N = 100. At the 50th percentile, a substantially narrower confidence interval was obtained for N = 100 (CI: 15 points) compared with N = 37 (CI: 25 points). Hence, this larger normative reference group was thought to represent a substantial improvement relative to the previous study. Based on this, the current study aimed to collect data for a sample of 100 participants for the norming study. The statistical package ICCSampleSize in R package version 1.0 (Rathbone, Shaw & Xxxxxxxx, 2015) was used to identify the sample size needed for test-retest and inter- rater reliability using intra-class correlation (ICC). To detect an effect size of 0.8, a sample size of 8 was found to give 80% power to detect effects of d = 0.8 where p = 0.05. A power analysis was conducted using G*Power (Xxxx, Erdfelder, Xxxx, & Xxxxxxx, 2007) to identify the sample size needed for parallel-form reliability. To detect a moderate effect size (0.6) a sample size of 45 for each group was found to give 80% power to detect effects of d = 0.6 or greater where p = 0.05. A power analysis was conducted to identify the sample size required for a construct validity analysis (i.e. comparing test performance on the CVWMT-I between the clinical and non-clinical groups). To detect a moderate effect size (0.5), guided by a preliminary study comparing scores on the ACT between controls and participants with severe TBI (Merkley, Xxxxxx, Xxxxxx & Good, 2013), a sample size of 51 for each group was found to give 80% power to detect effects of d = 0.5 or greater, where p = 0.05. To detect a correlation of 0.6 for convergent validity, a sample size of 47 was found to give 80% power to detect effects of d = 0.6 or greater where p = 0.05, using G*Power (Xxxx et al., 2007). Table 1.1 belo...
Sample 1
SAMPLE SIZE CALCULATIONS. The sample size (N = 36 [to allow at least 32 enrolled subjects to complete]) for this study is based on clinical and practical considerations and not on a formal statistical power calculation. The sample size is considered sufficient to effectively assess the PK and safety profiles of TPOXX.
Sample 1
SAMPLE SIZE CALCULATIONS. The study will employ a Group Sequential Design (see Section 6.2.2.2) and is powered accordingly. In order to estimate the required numbers of deaths and randomised subjects required to provide at least 90% power for a true (absolute) difference of 4.3% compared to a placebo mortality rate of 17% at 3 years, the computer program PEST4 was used [MPS Research Unit, 2000]. If the true rates of survival among subjects randomised to treatment are 87.3% with SERETIDE and 83% with placebo, then the hazard ratio for treatment with SERETIDE compared to placebo is HR = 0.728. A total of up to 440 deaths in these two groups would provide 90% power to detect such a difference. Note that the possibility of satisfying the stopping rule at either of the planned interim analyses implies that the actual number of deaths in this study may be somewhat lower than this upper limit. For comparative purposes, using a fixed sample approach, the number of deaths required to provide this level of power is estimated as 418. In order to provide 440 deaths, it is estimated that approximately 1510 subjects must be randomised to either group. If the true mortality rates for SERETIDE and FLIXOTIDE are similar, then a similar number of deaths (440) among subjects treated with either FLIXOTIDE or placebo will provide 90% power to detect a true difference between FLIXOTIDE and placebo equivalent to a hazard ratio of 0.728 or less. The effect of Salmeterol on mortality is expected to be somewhat lower than for either SERETIDE or FLIXOTIDE. The primary objective of the study with regards the inclusion of the Salmeterol arm is therefore to provide as precise an estimate of the magnitude of the mortality effect as is practically achievable. Therefore, it is planned that approximately 1510 subjects will be randomised to each of the four treatment groups in order to provide up to 880 deaths. However, if the actual mortality rates are either lower or higher than anticipated, the actual numbers randomised may be amended compared to the current plan.
Sample 1
SAMPLE SIZE CALCULATIONS. The sample size for this study is approximately 60 subjects. Each of the 3 cohorts will include 20 subjects (15 subjects receive AT-752 and 5 subjects receive placebo). XxXxx Low et al (Low 2014) , the observed standard deviations for VLR, defined as mean change from baseline viral load on days 2, 3, and 4, ranged from 0.75 (N=26) to 1.07 (N=24). Taking into account that the VLR endpoint in that study was based on an average of 3 measurements and assuming that there is some correlation between measurements on days 2 through 4, we consider power to detect a true effect at a single time point using a one-sided
Sample 1

Related to SAMPLE SIZE CALCULATIONS

  • DATA FOR CALCULATIONS The initial calculations for any payments owing under this Agreement shall be based upon the valuations placed upon the Qualified Property by the Appraisal District in its annual certified appraisal roll submitted to the District pursuant to § 26.01 of the TEXAS TAX CODE in or about July of each year of this Agreement. The certified appraisal roll data shall form the basis from which any and all amounts due under this Agreement are calculated, and the data utilized by the Consultant will be adjusted as necessary to reflect any subsequent adjustments by the Appraisal District to the District’s appraisal roll. Any estimates used by the Consultant to make calculations as required by this Agreement shall be based on the best and most current information available. The Consultant shall from time to time adjust the data utilized to reflect actual amounts, subsequent adjustments by the Appraisal District to the District’s certified appraisal roll, or any other relevant changes to material items such as student counts or tax collections.

  • DATA USED FOR CALCULATIONS The calculations for payments under this Agreement shall be initially based upon the valuations that are placed upon all taxable property in the District, including the Applicant’s Qualified Property, by the Appraisal District in its annual certified tax roll submitted to the District for each Tax Year pursuant to TEXAS TAX CODE § 26.01 on or about July 25 of each year of this Agreement. Immediately upon receipt of the valuation information by the District, the District shall submit the valuation information to the Third Party selected and appointed under Section 4.3. The certified tax roll data shall form the basis of the calculation of any and all amounts due under this Agreement. All other data utilized by the Third Party to make the calculations contemplated by this Agreement shall be based upon the best available current estimates. The data utilized by the Third Party shall be adjusted from time to time by the Third Party to reflect actual amounts, subsequent adjustments by the Appraisal District to the District’s certified tax roll or any other changes in student counts, tax collections, or other data.

  • Overtime Calculation For the purpose of overtime calculation only, approved or scheduled time off work will be considered the same as time worked.

  • Proration of calculations If less than total program funding is subject to interest calculation procedures, the resulting interest liability calculations shall be prorated to 100% of program funding.

  • Annual Evaluations The purpose of the annual evaluation is to assess and communicate the nature and extent of an employee's performance of assigned duties consistent with the criteria specified below in this Policy. Except for those employees who have received notice of non-reappointment pursuant to the BOT- UFF Policy on Non- reappointment, every employee shall be evaluated at least once annually. Personnel decisions shall take such annual evaluations into account, provided that such decisions need not be based solely on written faculty performance evaluations.

  • SUBMISSION OF THE MONTHLY MI REPORT 4.1 The completed MI Report shall be completed electronically and returned to the Authority by uploading the electronic MI Report computer file to MISO in accordance with the instructions provided in MISO.

  • Rental Rates and Wage Rates for Change Orders As soon as is practical, but prior to the completion of the Construction Preparation Period and in any event prior to the commencement of any Work on the Site, the Contractor shall submit in accordance with the style and format of a specimen to be furnished by the Owner for consideration of the Owner the following: (1) a proposal for rental rates on heavy construction equipment that shall apply in the event Change Order Work is performed, and (2) a proposal for wage rates for the types of project labor that shall apply in the event of the execution of any Change Order Work. Under penalty of false swearing, a principal of the contracting firm shall certify that the proposal for rental rates and proposal for wage rates do not exceed current costs for like services. The Owner will in no event consider a rental rate in excess of eighty percent of the rate set forth in the latest edition of the "Compilation of Nationally Averaged Rental Rates for Construction Equipment" of the Associated Equipment Distributors unless the rates proposed in excess of eighty percent are supported by proof satisfactory to the Owner that the excess rates are reasonable. If the equipment is owned by the Contractor the costs shall be charged at a maximum of eighty percent of market monthly rental rates for the amount of time used. If applicable, transportation costs may be included. The decision of the Owner shall be final, binding and conclusive on all parties. Rental rates shall be payable only for the actual time the equipment is required on the Site.

  • Monthly Updates The Contractor must provide the Design Professional and the Owner with monthly updates of the Overall Project Schedule indicating completed activities and any changes in sequencing or activity durations. (See also Articles 2.1.2 and 2.1.5).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!